Results 141 to 150 of about 32,411 (197)
Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database. [PDF]
NeurotherapeuticsXiang H +8 more
europepmc +1 more source
Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke. [PDF]
J NanobiotechnologyMigliavacca M +13 more
europepmc +1 more source
Stroke nurse-led intravenous thrombolytic therapy strategy for ischemic stroke based on timeline process: A quality improvement program from China. [PDF]
Int J Nurs SciLi B, Zhang Z, Li K, Zhao L, Niu R.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Surgical Clinics of North America, 1992
Thrombolytic therapy may be used as either sole treatment or an adjunct to surgery in both arterial and venous disease. The age of the clot, particularly with venous thrombosis, determines the probability of successful lysis, with recent clot being highly susceptible to lytic therapy.
P F, Lawrence, G R, Goodman
openaire +4 more sources
Thrombolytic therapy may be used as either sole treatment or an adjunct to surgery in both arterial and venous disease. The age of the clot, particularly with venous thrombosis, determines the probability of successful lysis, with recent clot being highly susceptible to lytic therapy.
P F, Lawrence, G R, Goodman
openaire +4 more sources
Annual Review of Medicine, 1988
Thrombolytic agents are plasminogen activators that convert plasminogen, the inactive proenzyme of the fibrinolytic system in blood, to the proteolytic enzyme plasmin. Plasmin in turn dissolves the fibrin of a blood clot, but may also degrade normal components of the hemostatic system and predispose to bleeding. The first-generation thrombolytic agents,
D, Collen, D C, Stump, H K, Gold
+7 more sources
Thrombolytic agents are plasminogen activators that convert plasminogen, the inactive proenzyme of the fibrinolytic system in blood, to the proteolytic enzyme plasmin. Plasmin in turn dissolves the fibrin of a blood clot, but may also degrade normal components of the hemostatic system and predispose to bleeding. The first-generation thrombolytic agents,
D, Collen, D C, Stump, H K, Gold
+7 more sources
Annals of Emergency Medicine, 1993
All patients with symptoms and ECG findings suggestive of acute myocardial infarction (AMI) should be considered for treatment with thrombolytic agents. The decision to use thrombolytic therapy is a clinical judgment based upon a weighing of the potential benefits versus the possible risks.
Eisenberg, M. +5 more
openaire +3 more sources
All patients with symptoms and ECG findings suggestive of acute myocardial infarction (AMI) should be considered for treatment with thrombolytic agents. The decision to use thrombolytic therapy is a clinical judgment based upon a weighing of the potential benefits versus the possible risks.
Eisenberg, M. +5 more
openaire +3 more sources
Emergency Medicine Clinics of North America, 1995
If the electrocardiogram is diagnostic of acute myocardial infarction (AMI) in the patient complaining of typical chest pain, then indications and contraindications for thrombolytic therapy must be assessed immediately. The goal is to administer a thrombolytic agent within 30 to 60 minutes of presentation to the emergency department.
G P, Young, J R, Hoffman
openaire +2 more sources
If the electrocardiogram is diagnostic of acute myocardial infarction (AMI) in the patient complaining of typical chest pain, then indications and contraindications for thrombolytic therapy must be assessed immediately. The goal is to administer a thrombolytic agent within 30 to 60 minutes of presentation to the emergency department.
G P, Young, J R, Hoffman
openaire +2 more sources